Skip to main content
Download PDF

Outcomes of deep venous thrombosis management and associated factors among patients in tertiary hospitals in Addis Ababa, Ethiopia: a multicenter retrospective cohort study

Thrombosis Journal volume 22, Article number: 62 (2024) Cite this article

Abstract

Background

Pulmonary embolism (PE) and deep venous thrombosis (DVT) are the two most important manifestations of venous thromboembolism (VTE). DVT remains a significant condition since associated morbidity is significant and has elevated healthcare-related costs.

Methods

A retrospective cohort study was conducted among DVT patients admitted to Tikur Anbessa Specialized Hospital, Zewditu Memorial Hospital and St. Paul’s Hospital Millennium Medical College on follow-up from July 1, 2017, to July 01, 2020. Data on sociodemographic characteristics, types of DVT, laboratory findings, medications, risk factors of DVT, complications and outcomes of DVT were collected. The data were analyzed using SPSS version 25. Multivariate logistic regression analysis was conducted to determine predictors of DVT recurrence and major bleeding. A P value < 0.05 was considered to identify significant predictors.

Results

The mean age of the participants was 45.2 years, with SD of 15.36. The major causes of DVT included immobilization (29.9%), previous surgery (27.5%) and cancer (21.1%). The DVT recurrence rate was 22.5%. Nine (2.2%) of the participants died, and 19.9% developed complications. Bilateral DVT (Adjusted odds ratio (AOR) = 2.8, 95% Confidence interval (CI) = 1.14, 6.66), obesity (AOR = 3.3, 95% CI = 1.15, 9.59), hypertension (AOR = 6.5, 95% CI = 2.90, 14.70) and retroviral infection (AOR = 6.3, 95% CI = 2.34, 16.94) were predictors of recurrent DVT. Nineteen (4.7%) patients had major bleeding, and patients with bilateral DVT, active cancer and terminal age had an increased risk of major bleeding.

Conclusions

The overall DVT recurrence rate was alarmingly high and further complicated by PE, post thrombotic syndrome and chronic vein insufficiency, resulting in a 2.2% death rate. Major bleeding after DVT and PE remained high. Close monitoring should be performed for patients with advanced age, active cancer, bilateral DVT, retroviral infection, obesity and hypertension to prevent the recurrence of DVT and major bleeding.

Introduction

Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and/or pulmonary embolism (PE), is a common, severe, potentially fatal but manageable acute condition. Approximately 0.1% of the global population each year develop DVT [1]. DVT is a complex multifactorial disease and an important cause of preventable mortality and morbidity [2]. The incidence of DVT increases sharply after approximately 45 years of age and is slightly greater in men than in women of advanced age. Major risk factors for thrombosis, other than age, include exogenous factors such as surgery, hospitalization, immobility, trauma, pregnancy, and puerperium and hormone use and endogenous factors such as cancer, obesity, and inherited and acquired disorders of hypercoagulation [3].?75 years had a 6.8-fold greater incidence of major bleeding than did those aged younger than 75 years (AOR?=?6.8, 95% CI?=?2.03, 22.33) (Table 6)." Furthermore, the heading "Predictors of recurrent DVT and major bleeding" shall be "Predictors of recurrent DVT""?>

Globally, DVT remains a significant condition since associated morbidity is significant and has elevated healthcare-related costs [4]. DVT and associated complications are common in hospital settings, but they are also becoming more common among outpatients. The incidence of VTE was 5.5% among hospitalized patients in a study conducted in Addis Ababa [5]. A study from Addis Ababa and Jimma reported that the recurrence rate of DVT was 26.4%, which is higher than most previously published data [6]. A study conducted in Canada revealed that the rates of recurrent VTE after DVT and PE remain unacceptably high, where one-fifth of cases experienced recurrent VTE [7]. According to a study in the US, DVT contributes to the deaths of 33% of those affected [8]. VTE is a major health problem in Europe, with more than one million VTE events or deaths per year in the six countries examined. Almost three-quarters of all VTE-related deaths were reported from hospital-acquired VTE [9].

According to the Centers for Disease Control and Prevention (CDC), one-third of patients diagnosed with DVT/PE experience recurrence within 10 years, and up to 50% develop post thrombotic syndrome (PTS) [10]. The frequency of recurrent DVT is increasing, making early identification and treatment of risk factors that predispose patients to recurrence critical.

The aim of treatment for DVT is to reduce morbidity and mortality. This is achieved by optimal therapy with anticoagulants to prevent thrombus extension and embolization, thus preventing recurrence and death, which exposes patients to an inherent increased risk of bleeding [11]. In a study from Canadan, among patients with DVT, 12.8% developed major bleeding during the follow-up period [7].

There is a dearth of information available in Ethiopia on the outcomes of DVT treatment and the risk factors for its recurrence. Most prior studies that examined the recurrence rate of DVT in Ethiopia had limited sample sizes and relied on nonmulticenter data, and most disregarded secondary outcomes such as major bleeding. Therefore, this study was conducted to evaluate treatment outcomes and associated factors among DVT patients receiving anticoagulation therapy at three tertiary care hospitals, namely, Tikur Anbessa Specialized Hospital (TASH), St. Paulos Hospital Millennium Medical College (SPHMMC) and Zewuditu Memorial Hospital (ZMH), in Addis Ababa.

Methods and materials

Study design, area and period

A retrospective cohort study was conducted among DVT patients at SPHMMC, ZMH and TASH. We chose these hospitals because they are referral hospitals which allows us to find diverse participants. During the data collection period, there were approximately 720 patients under regular follow-up at the clinics of the hospitals, with an average of 30 patients seen at each clinic daily. The data were collected from October 1, 2020 to March 31, 2021.

Population

DVT patients at TASH, SPHMMC and ZMH who were on follow-up between July 1, 2017, and July 1, 2020, who were aged 18 years and older, and who were on anticoagulants for at least 3 months or more were included. DVT patients who had incomplete data or medical records were excluded from the study.

Sample size determination

A total of 408 study participants were included using a single proportion population formula and were proportionally allocated to TASH, SPHMMC or ZMH. Systematic random sampling techniques were employed to select participants.

Data collection tools and procedures

The data collection tool was developed by using different studies [12,13,14]. The data collected included sociodemographic characteristics, types of DVT, laboratory findings, a list of all medications, risk factors and clinical data, complications and outcomes of DVT. Information about the category of bleeding that occurred during the treatment period was evaluated based on the International Society on Thrombosis and Hemostasias [14]. All the data were collected from patient medical records.

The data were collected by two trained data collectors, one nurse and one pharmacist trained on the objective of the study and the contents of the questionnaire.

The validity of the study was checked by a pretest performed on 5% of the study population at St. Peter Specialized Hospital with similar characteristics to ensure the agreement of the data abstraction format with the needs of the study. Modifications were mainly made to the variables used to measure DVT treatment outcomes and were corrected and modified into the final version of the data collection tool. Continuous supervision was provided by the principal investigator to ensure the completeness and consistency of the collected data. All collected data were examined for completeness and consistency during data management, storage and analysis.

Data Analysis

The data were collected and entered into Epi info 4.6.0.6 and analyzed using Statistical Package for the Social Sciences (SPSS) version 25. Descriptive statistics such as frequency, percentage, mean, and standard deviation (SD) were used to describe demographic and clinical features, as well as the outcomes. Logistic regression models were used to determine whether the sociodemographic data, laboratory findings and comorbid conditions were related to outcomes such as recurrent DVT and major bleeding. Candidate variables possibly associated with the outcome variables (P value < 0.25) after bivariate analysis were included in the multivariable logistic regression model. A P value < 0.05 was considered a significant predictor of the outcome.

Outcome measures

The primary outcomes for the study were recurrence, major bleeding and death, whereas the secondary outcomes were factors for recurrent DVT and major bleeding.

Definition of terms

DVT recurrence

was defined as an objectively verified hospital discharge diagnosis of DVT, a fatal complication of DVT confirmed by ultrasonography, or a site of thrombosis that was either previously uninvolved or had interval documentation of incident DVT [14].

Major bleeding

included fatal bleeding; retroperitoneal, intracranial, or intraocular bleeding; bleeding that causes hemodynamic compromise requiring specific treatment; bleeding that requires intervention (surgical or endoscopic) or decompression of a closed space to stop or control the event; clinically overt bleeding, requiring any transfusion of one unit or more of packed red blood cells or whole blood; and clinically overt bleeding, causing a decrease in hemoglobin of 3 g/dL or more (or, if the hemoglobin level is not available, a decrease in hematocrit of 10% or greater) [15].

Complication

Complications from deep vein thrombosis can be very serious. It includes pulmonary embolism (PE), chronic venous insufficiency, and post thrombotic syndrome [16].

Results

Sociodemographic and clinical characteristics

The study sample consisted of 408 men and women from the three hospitals during the three-year study period and included patients who had taken anticoagulant medication for at least 3 months. The mean age and SD of the study participants were 45.2 and 15.36 years, respectively. As shown in Table 1, approximately one-third (36.5%) of the participants were in the ≥ 51 years age group. More than half (58.8%) of the participants were female.

The majority of DVT patients reported had lower limb thrombosis (95.3%), followed by unilateral (78.7%) and proximal DVT (40.4%). Regarding the presence of signs and symptoms, more than three-fourths of the studied patients had pitting edema, and all the studied patients experienced pain and swelling. Among the risk factors for DVT, immobilization was associated with 29.9% of the patients, surgery was associated with 27.5% of the patients, and the other risk factors were summarized. The most commonly reported comorbid diseases were hypertension (30.4%), diabetes mellitus (11.8%), retroviral infection (11.4%), and malignant diseases (62, 15%). Breast cancer was the most common cancer, accounting for 29% of the malignant cases, followed by ovarian, cervical, rectal and liver cancers. 18% of the participants had a prior history of surgery (Table 1).

Table 1 Sociodemographic characteristics and clinical profiles of study participants with DVT at selected hospitals in Addis Ababa, July 1, 2017 to July 1, 2020
Full size table

The majority of the study participants were taking warfarin (79.4%), along with either unfractionated heparin (80.8%) or enoxaparin (19.1%), and the rest were taking rivaroxaban (20.6%). All of the study participants were on anticoagulants. Among a total of 408 DVT patients, 204 had comorbid conditions and were taking concurrent medications. The majority of these patients were taking antibiotics, followed by cardiovascular, vitamin K, and antidiabetic drugs, as shown in Table 2.

Table 2 Anticoagulants and other medications used for the management of DVT and comorbidities at selected hospitals in Addis Ababa, July 01, 2017 - July 01, 2020
Full size table

The following table presents the bleeding status of the DVT patients. The results showed that 42 (10.0%) patients had a history of bleeding, and 19 (4.7%) had major bleeding (Table 3).

Table 3 Bleeding status of the study participants according to the International Society on Thrombosis and Hemostasias guidelines at selected hospitals in Addis Ababa, July 01, 2017 - July 01, 2020
Full size table

According to our study findings, the incidence of recurrent DVT was 22.5%, and the majority of patients experienced two recurrences of DVT (20.1%). After treatment with anticoagulants, 17.9% of patients were completely resolved, 10% worsened, and 2.2% died. Approximately one-fifth (19.9%) of the study participants developed complications, and PE accounted for 44.4%, followed by PTS and chronic vein insufficiency (Table 4).

Table 4 DVT treatment outcomes at selected hospitals in Addis Ababa, July 01, 2017 - July 01, 2020
Full size table

Predictors of recurrent DVT

The results of the multivariate logistic regression analysis showed that bilateral DVT, obesity, hypertension and the RVI were significantly associated with DVT recurrence. Accordingly, participants with bilateral DVT had a 2.8-fold greater likelihood of recurrence than did participants with unilateral DVT (AOR = 2.8, 95% CI = 1.14, 6.66), and obese participants had a 3.3-fold greater likelihood of recurrence than did participants with a normal body mass index (AOR = 3.3, 95% CI = 1.15, 9.59). Participants with hypertension had a 6.5-fold greater recurrence of DVT than did nonhypertensive patients (AOR = 6.5, 95% CI = 2.90, 14.70), while RVI patients had a 6.3-fold greater recurrence of DVT than did their counterparts (AOR = 6.3, 95% CI = 2.34, 16.94) (Table 5).

Table 5 Multivariate binary logistic regression analysis of predictor factors for DVT recurrence among study participants at selected hospitals in Addis Ababa, July 01, 2017 - July 01, 2020
Full size table

Predictors of major bleeding

In addition, the strength of the association between the independent variable and major bleeding was alsomeasured using a 95% confidence interval and odds ratio. Accordingly, DVT type, the presence of active cancer and age older than 75 years were associated with major bleeding according to multivariable logistic regression analysis.

Patients with bilateral DVT had a 3.9-fold increase in major bleeding compared with patients with unilateral DVT (AOR = 3.9, 95% CI = 1.6, 9.7), and participants with active cancer disease had a 6.5-fold increase in major bleeding compared with those with no active cancer (AOR = 6.5, 95% = 2.9, 14.75). Participants aged >75 years had a 6.8-fold greater incidence of major bleeding than did those aged younger than 75 years (AOR = 6.8, 95% CI = 2.03, 22.33) (Table 6).

Table 6 Multivariate binary logistic regression analysis of predictors associated with major bleeding at selected hospitals in Addis Ababa, July 01, 2017 - July 01, 2020
Full size table

Discussion

The current study investigated the incidence and predictors of recurrent DVT in three selected tertiary hospitals in Addis Ababa, Ethiopia. A higher rate of recurrent DVT was reported, accounting for 22.5%. Nine participants (2.2%) died, and 19.9% of patients developed complications. PE accounted for 44.4% of these complications, followed by PTS and chronic vein insufficiency. Forty-two participants (10%) experienced bleeding episodes, and 4.7% of the participants experienced major bleeding.

Among the signs and symptoms, pain and general swelling manifested in all patients. Similar findings were reported in Ethiopia and Hong Kong [6, 17]. Unilateral limb involvement was observed in 78.7% of the patients. A higher percentage of unilateral involvement was also previously reported in Addis Ababa [18]. Our study also showed that the majority of the patients (95.3%) had DVT in their lower limbs, which is in line with a study performed in Zambia [19] and Hong Kong [17].

Our findings showed that the most common causes of DVT were a longer hospital stay (immobilization) (29.9%), previous surgery (27.5%), active cancer (21.1%), previous VTE (20.6%), acute infection (19.6%), pregnancy (15.7%), heart failure (5.6%), prior history of trauma (4.2%), presumed genetic disorders (2.2%) and age ≥ 75 years (8.1%), while the remaining 23% had unprovoked DVT. According to a previous study performed in Addis Ababa [18], the most commonly noted causes of DVT were malignancy of any kind (30.9%) and prolonged immobilization (19.8%). The difference may be that the current study was a multicenter study. Likewise, a study from America [1] reported that cancer was also a common comorbid condition, affecting 36.4% of all patients, while recent immobility and/or injury were found in 41.9% of the cohort and 22.8% of patients with the event classified as unprovoked. The finding of unprovoked risks was similar to our findings. In contrast, a study in Nigeria [20] showed that only 2% were unprovoked. This variation might be due to the smaller sample size used in the Nigerian study.

The incidence of recurrent DVT was 22.5%, and the majority of patients experienced two recurrences of DVT (20.1%). This finding was comparable to those of previous studies performed in Ethiopia [6] and the USA [21], which reported DVT recurrence rates of 26.4% and 26.1%, respectively. However, a lower incidence of recurrent DVT has been reported elsewhere [22]. The variation might be attributed to methodological differences and patient care disparities in various settings.

The results of the multivariate logistic regression analysis showed that bilateral DVT, obesity, hypertension and RVI were significantly associated with DVT recurrence. In our study, the odds of recurrent DVT were 6.5 times greater among patients with hypertension than among patients without hypertension. Similarly, hypertension was a predictor of recurrent DVT in a meta-analysis [23]. This could be explained by elevated blood pressure causing damage to venous valves, resulting in obstruction of blood vessels [24], and hypertension can also be associated with hypercoagulability [25].

In addition, the odds of developing recurrent DVT among people living with HIV (PLWH) were 6.3 times greater than those among their counterparts. A similar finding was also reported in the Netherlands, where the risk of recurrent VTE was elevated in PLWH compared to controls [26]. HIV-associated immunosuppression, opportunistic infections, malignancies and coagulopathy abnormalities contribute to an increased risk of recurrent DVT [27].

Our findings revealed that bilateral DVT was associated with a 2.8-fold increase in recurrent DVT. Similarly, a report from Qatar revealed that bilateral DVT predisposes patients to recurrent DVT [28].

The risk of recurrent DVT among obese patients was 3.3 times greater than that among nonobese patients. Similar findings were reported elsewhere [23, 29]. Although the pathophysiologic mechanisms underlying the contribution of obesity to recurrent DVT have not been fully explained, several speculated factors might play a role. Obesity may be associated with a prothrombotic state characterized by increased levels of procoagulant factors and decreased levels of anticoagulant factors [30].

Our study revealed that 9 (2.2%) of the participants died during the study period. The most common complication causing death was PE. This was comparable to that observed in the Worcester Venous Thromboembolism Study [7], where patients who presented with PE had a significantly greater overall death rate than those who presented with isolated DVT. In addition, Labropoulos et al. reported an association between PE and death [21].

Our data showed that 19.9% of patients developed complications, 44.4% of whom developed PE, 38.3% of whom developed PTS, and 17.3% of whom experienced chronic vein insufficiency. The CDC reported that 33–50% of people who have experienced DVT will experience long-term complications (post thrombotic syndrome), which include swelling, pain, discoloration, and scaling in the affected limb [31]. A study from Sweden showed that 26% of the study population developed PTS, 12% recurrent DVT, and 9% PE [32].

Our findings revealed that 4.7% of patients experienced major bleeding. Similar results were reported for Sweden (4.0%) [33] and Denmark (6.6%) [34]. The type of DVT (bilateral DVT), presence of active cancer and age above 75 years were associated with major bleeding. The likelihood of developing major bleeding among patients with bilateral DVT was 3.9 times greater than that among patients with unilateral DVT. This finding could be partly explained by the fact that bilateral DVT can cause major bleeding due to the extensive clot burden and the disruption of blood vessels [35], and intensive anticoagulation therapy further increases the risk of bleeding [36]. Participants with active cancer had a 6.5-fold increase in major bleeding. This finding is in line with a study from Japan [37]. This is explained by the complex nature of the pathophysiology of cancer and associated chemotherapy-induced bleeding [38]. Participants aged more than 75 years had a 6.8-fold increased risk of major bleeding. This was supported by another study performed in Italy [39].

Some investigations, including ours, have indicated that an age greater than 75 years is related to an increased risk of bleeding; hence, this parameter has been incorporated in the calculation of bleeding risk scores [39, 40]. Similar findings were reported elsewhere [41, 42], indicating that old age is a contributing factor to the risk of bleeding. This might be due to risk factors such as cancer, stroke, heart failure, immobilization, and a history of VTE, which are more common in the elderly population and contribute to a greater incidence of bleeding events [33].

In resource limited settings, the management and follow-up of DVT present unique challenges. Initial management typically involves intensive anticoagulant therapy, such as low molecular weight heparin or direct-acting oral anticoagulants, although access to these medications is limited. Follow-up care often relies on outpatient clinics, where patients may face barriers to regular attendance due to distance, transportation costs, or competing socioeconomic interests. These challenges contribute to suboptimal adherence to treatment and monitoring protocols, increasing the risk of recurrence and complications. Moreover, lack of specialty care facilities and trained health professionals may hinder the diagnosis and management of DVT complications, such as bleeding events. The implications of these systemic challenges are significant, potentially exacerbating the burden of recurrent and complications of DVT. Efforts to address these issues should prioritize improving access to essential medications, enhancing healthcare infrastructure, and support patient adherence and follow-up care.

This research employed a larger sample size in multiple study settings than did previous studies in Ethiopia. We aimed to incorporate key outcomes of DVT, including recurrence, mortality, complications, major bleeding, and predictive factors for recurrence and major bleeding, which have not been thoroughly examined in prior studies. However, our study is not without limitations. Since it is a retrospective study, it is predisposed to recall bias. We encountered instances of incomplete recording by providers or insufficient information regarding relevant findings, such as subjective bleeding assessments being unavailable in many cases. Additionally, most of the data associated with the INR were not recorded. Despite these limitations, our study provides valuable insights and offers important recommendations for future research and clinical practice.

Conclusions

In the current study, the overall DVT recurrence rate was 22.5%, which was complicated by PE, PTS and chronic vein insufficiency, resulting in 2.2% death. Major bleeding rates after DVT and PE remain high. Efforts are needed to identify patients who are most at risk for VTE complications, and developing better anticoagulation strategies that are suitable for long-term use is crucial for better patient treatment outcomes. Close monitoring should be performed for patients with advanced age, active cancer, bilateral DVT, RVI, obesity and hypertension to prevent the recurrence of DVT and major bleeding.

Data availability

No datasets were generated or analysed during the current study.

Abbreviations

DOAC:

Direct oral anticoagulant

DVT:

Deep vein thrombosis

INR:

International normalized ratio

LMWH:

Low-molecular-weight heparin

NOAC:

Nonvitamin K antagonist oral anticoagulants

PE:

Pulmonary embolism

PT:

Prothrombin time

PTS:

Post thrombotic syndrome

RVI:

Retroviral infection

VTE:

Venous thromboembolism

VKA:

Vitamin K-Antagonist

References

  1. Fang MC, Fan D, Sung SH, Witt DM, Schmelzer JR, Williams MS, Yale SH, Baumgartner C, Go AS. Treatment and outcomes of acute pulmonary embolism and deep venous thrombosis: the CVRN VTE study. Am J Med. 2019;132(12):1450–7. e1451.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Al-Khafaji RA, Schierbeck L. Deep venous thrombosis in a patient with a moderate Pretest Probability and a negative D-Dimer test: a review of the Diagnostic algorithms. J Blood Med 2020:173–84.

  3. Khalil L, Wong HS, Keeling DM, Desborough MJ. Venous thromboembolism: risk of recurrence and long-term anticoagulation. In.: MA Healthcare London; 2015.

  4. Lang KJ, Saha P, Roberts LN, Arya R. Changing paradigms in the management of deep vein thrombosis. Br J Haematol. 2015;170(2):162–74.

    Article  PubMed  Google Scholar 

  5. Ahmed F, Hussen S, Assefa T. Venous thromboembolism risk, prophylaxis and outcome in hospitalized patients to medical wards of university teaching hospital. J Clin Exp Cardiolog. 2019;10(1):13–5.

    Article  Google Scholar 

  6. Mulatu A, Melaku T, Chelkeba L. Deep venous thrombosis recurrence and its predictors at selected tertiary hospitals in Ethiopia: a prospective cohort study. Clin Appl Thromb Hemost. 2020;26:1076029620941077.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester venous thromboembolism study. Arch Intern Med. 2008;168(4):425–30.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Vululi ST, Bugeza S, Zeridah M, Ddungu H, Openy AB, Frank M, Parkes-Ratanshi R. Prevalence of lower limb deep venous thrombosis among adult HIV positive patients attending an outpatient clinic at Mulago Hospital. AIDS Res Therapy. 2018;15:1–7.

    Article  Google Scholar 

  9. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98(10):756–64.

    Article  CAS  PubMed  Google Scholar 

  10. Control CfD. Prevention: data and statistics on venous thromboembolism. Centers Dis Control Prev 2020.

  11. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson C-G, Turpie AG. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164(9):963–8.

    Article  PubMed  Google Scholar 

  12. Yusuf HR, Reyes N, Zhang QC, Okoroh EM, Siddiqi A-E-A, Tsai J. Hospitalizations of adults ≥ 60 years of age with venous thromboembolism. Clin Appl Thromb Hemost. 2014;20(2):136–42.

    Article  PubMed  Google Scholar 

  13. Patel P, Patel P, Bhatt M, Braun C, Begum H, Nieuwlaat R, Khatib R, Martins CC, Zhang Y, Etxeandia-Ikobaltzeta I. Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis. Blood Adv. 2020;4(12):2779–88.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.

    Article  PubMed  Google Scholar 

  15. Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost. 2014;112(08):255–63.

    Article  CAS  PubMed  Google Scholar 

  16. Hamandi M, Lanfear AT, Woolbert S, Bolin ML, Fan J, William M, Khan Z, DiMaio JM, Dib C. Challenging management of a patient with severe bilateral deep vein thrombosis. J Investig Med High Impact Case Rep. 2020;8:2324709620910288.

    PubMed  PubMed Central  Google Scholar 

  17. Lee Y, Ting A, Cheng S. Diagnosing deep vein thrombosis in the lower extremity: correlation of clinical and duplex scan findings. Hong Kong Med J = Xianggang Yi Xue Za zhi/Hong Kong Acad Med 2002.

  18. Haile L, Hawaz Y, Assefa G. Risk factors of deep venous thrombosis in duplex and colour doppler ultrasound at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. East Cent Afr J Surg. 2013;18(2):61–9.

    Google Scholar 

  19. Mwandama CK, Andrews B, Lakhi S. Prevalence of deep vein thrombosis and associated factors in adult medical patients admitted to the University Teaching Hospital, Lusaka, Zambia. Med J Zambia. 2016;43(4):224–30.

    Article  Google Scholar 

  20. Ahmed S, Tahir A, Hassan A, Kyari O, Ibrahim U. Clinical risk factors for deep vein thrombosis in Maiduguri-Nigeria. Highland Med Res J. 2003;1(4):9–16.

    Google Scholar 

  21. Labropoulos N, Jen J, Jen H, Gasparis AP, Tassiopoulos AK. Recurrent deep vein thrombosis: long-term incidence and natural history. Ann Surg. 2010;251(4):749–53.

    Article  PubMed  Google Scholar 

  22. Chen Y, Tang B, Nie M, Qi X, Wang F, Wang H. The incidence, risk factors, characteristics, and prognosis of recurrent deep venous thrombosis in the contralateral lower extremity. J Vascular Surgery: Venous Lymphatic Disorders. 2023;11(1):52–60.

    CAS  PubMed  Google Scholar 

  23. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56(1):1–7.

    Article  PubMed  Google Scholar 

  24. Lim AU, de Jesus M, Posas FE, Martinez M. Poster 043 a case of Post thrombotic syndrome and AV Fistula arising from recurrent DVT secondary to May–Thurner Syndrome (MTS) in an Elderly Woman. Cardiovascular Res. 2022;118(Supplement2):cvac157.

    Google Scholar 

  25. McLafferty RB. Endovascular management of deep venous thrombosis. Perspect Vasc Surg Endovasc Ther. 2008;20(1):87–91.

    Article  PubMed  Google Scholar 

  26. Rokx C, Borjas Howard JF, Smit C, Wit FW, Pieterman ED, Reiss P, Cannegieter SC, Lijfering WM, Meijer K, Bierman W. Risk of recurrent venous thromboembolism in patients with HIV infection: a nationwide cohort study. PLoS Med. 2020;17(5):e1003101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Jackson BS, Pretorius E. Pathological clotting and deep vein thrombosis in patients with HIV. Seminars in thrombosis and hemostasis: 2019. Thieme Medical; 2019. pp. 132–40.

  28. Asim M, Al-Thani H, El-Menyar A. Recurrent deep vein thrombosis after the first venous thromboembolism event: a single-institution experience. Med Sci Monitor: Int Med J Experimental Clin Res. 2017;23:2391.

    Article  Google Scholar 

  29. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168(15):1678–83.

    Article  PubMed  Google Scholar 

  30. Nabli F, Daadaa S, Boussoukaya Y, Chaabene I, Kechida M, Klii R, Hammami S. AB1448 DEEP VENOUS THROMBOSIS IN YOUNG ADULTS: INCIDENCE AND RISK FACTORS. In. BMJ Publishing Group Ltd; 2022.

  31. Van der Hulle T, Kooiman J, Den Exter P, Dekkers O, Klok F, Huisman M. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320–8.

    Article  PubMed  Google Scholar 

  32. Hansson P-O, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160(6):769–74.

    Article  CAS  PubMed  Google Scholar 

  33. Wallvik N, Renlund H, Själander A. Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants. J Thromb Thrombolysis. 2021;52:315–23.

    Article  CAS  PubMed  Google Scholar 

  34. Dalager-Pedersen M, Lund LC, Mariager T, Winther R, Hellfritzsch M, Larsen TB, Thomsen RW, Johansen NB, Søgaard OS, Nielsen SL. Venous thromboembolism and major bleeding in patients with coronavirus disease 2019 (COVID-19): a nationwide, population-based cohort study. Clin Infect Dis. 2021;73(12):2283–93.

    Article  CAS  PubMed  Google Scholar 

  35. Lamdhade S, Dashti R, Thussu A, Alroughani R. Answer: bilateral femoral neuropathy due to bilateral iliopsoas hematoma in a young patient with acute myocardial infarction. Ann Saudi Med. 2014;34(3):1.

    Article  PubMed Central  Google Scholar 

  36. Munoz J, Hong D, Kurzrock R. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. Int J Hematol. 2012;95:1–2.

    Article  PubMed  Google Scholar 

  37. Nishimoto Y, Yamashita Y, Kim K, Morimoto T, Saga S, Amano H, Takase T, Hiramori S, Oi M, Akao M. Risk factors for major bleeding during anticoagulation therapy in Cancer-Associated venous Thromboembolism―From the COMMAND VTE Registry―. Circ J. 2020;84(11):2006–14.

    Article  CAS  PubMed  Google Scholar 

  38. Sabatino J, De Rosa S, Polimeni A, Sorrentino S, Indolfi C. Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis. Cardio Oncol. 2020;2(3):428–40.

    Google Scholar 

  39. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood J Am Soc Hematol. 2002;100(10):3484–8.

    CAS  Google Scholar 

  40. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91–9.

    Article  CAS  PubMed  Google Scholar 

  41. Frei AN, Stalder O, Limacher A, Méan M, Baumgartner C, Rodondi N, Aujesky D. Comparison of bleeding risk scores in elderly patients receiving extended anticoagulation with vitamin K antagonists for venous thromboembolism. Thromb Haemost. 2021;121(11):1512–22.

    Article  PubMed  Google Scholar 

  42. Li L, Zhen J, Huang L, Zhou J, Yao L, Xu L, Zhang W, Zhang G, Chen Q, Cheng B. The risk factors for deep venous thrombosis in critically ill older adult patients: a subgroup analysis of a prospective, multicenter, observational study. BMC Geriatr. 2022;22(1):977.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Tikur Anbessa Specialized Hospital, St. Peter Specialized Hospital, St. Paul’s Hospital Millennium Medical College and Zewditu Memorial Hospital and staff members for their cooperation and permission to conduct this study. We would also like to express our appreciation to the data collectors.

Funding

This research received no external funding.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia

    Seble Birhane, Melak Gedamu Beyene & Assefa Mulu Baye

  2. Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia

    Fishatsion Tadesse

Authors
  1. Seble Birhane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melak Gedamu Beyene
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fishatsion Tadesse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Assefa Mulu Baye
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SB and AMB were involved in the inception and methodology of the study and data curation.SB, MGB, FT, and AMB validated, analyzed, wrote and edited the draft manuscript.All authors reviewed the manuscript.All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Assefa Mulu Baye.

Ethics declarations

Ethics approval and consent to participate

Ethical approval was obtained from the Ethical Review Committee (ERC) of School of Pharmacy, Addis Ababa University (Ref; ERB/SOP/266/13/2021) and the Institutional Review Board (IRB) of St Paul Hospital Millennium Medical College (Ref; P423/389). The study was conducted according to the Declaration of Helsinki. This study utilized secondary data collected from medical records of study participants for the purpose of evaluating the outcomes DVT management and its predictors. The data utilized in this study are anonymized, and thus do not contain any personally identifiable information that could compromise the privacy or confidentiality of participants.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Birhane, S., Beyene, M.G., Tadesse, F. et al. Outcomes of deep venous thrombosis management and associated factors among patients in tertiary hospitals in Addis Ababa, Ethiopia: a multicenter retrospective cohort study. Thrombosis J 22, 62 (2024). https://doi.org/10.1186/s12959-024-00627-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12959-024-00627-2

Keywords

Thrombosis Journal

ISSN: 1477-9560

Contact us